The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.
 
Benjamin M. Ellingson
Consulting or Advisory Role - Alpheus Medical; Chimerix; Ellipses Pharma; Global Coalition for Adaptive Research; Imaging Endpoints; ImmunoGenesis; Janssen; Kazia Therapeutics; Medicenna; MedQIA; Monteris Medical; Neosoma; SERVIER; Siemens; Sumitomo Dainippon Pharma Oncology; VBL Therapeutics
Research Funding - Janssen; Siemens
Travel, Accommodations, Expenses - Siemens
 
Akifumi Hagiwara
No Relationships to Disclose
 
Connor Morris
No Relationships to Disclose
 
Nicholas Cho
No Relationships to Disclose
 
Sonoko Oshima
No Relationships to Disclose
 
Francesco Sanvito
No Relationships to Disclose
 
Talia Oughourlian
No Relationships to Disclose
 
Catalina Raymond
No Relationships to Disclose
 
Lauren E. Abrey
Employment - Novartis; Novartis (I)
Stock and Other Ownership Interests - Novartis; Novartis (I)
 
Josep Garcia
No Relationships to Disclose
 
Dana T. Aftab
Employment - Exelixis
Leadership - Exelixis
Stock and Other Ownership Interests - Exelixis
Patents, Royalties, Other Intellectual Property - Cabozantinib (Inst)
 
Colin Hessel
Employment - Exelixis
Leadership - Exelixis
Stock and Other Ownership Interests - Exelixis
 
Tamar Rachmilewitz Minei
Employment - VBL Therapeutics
Leadership - VBL Therapeutics
Stock and Other Ownership Interests - VBL Therapeutics
 
Shifra Fain Shmueli
Employment - VBL Therapeutics
Leadership - VBL Therapeutics
Stock and Other Ownership Interests - VBL Therapeutics
 
David Nathanson
Leadership - Katmai Pharmaceuticals; Trethera
Stock and Other Ownership Interests - Katmai Pharmaceuticals; SOFIE; Trethera
Research Funding - ABBVIE/ABBOTT; AstraZeneca; Erasca, Inc; Roche; Sanofi
 
Patrick Y. Wen
Consulting or Advisory Role - AstraZeneca; Bayer; Black Diamond Therapeutics; Boehringer Ingelheim; Boston Pharmaceuticals; Celularity; Chimerix; Day One Biopharmaceuticals; ElevateBio; Genenta Science; GlaxoSmithKline; Insightec; Integral Health; Karyopharm Therapeutics; Merck; Mundipharma; Novartis; Novocure; Novocure; Nuvation Bio; Prelude Therapeutics; Prelude Therapeutics; Sagimet Biosciences; Sapience Therapeutics; Servier; Servier; Vascular Biogenics; VBI Vaccines
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Celgene (Inst); Chimerix (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Oncoceutics (Inst); Puma Biotechnology (Inst); Servier (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Chimerix; Katmai Pharmaceuticals; Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; DelMar Pharmaceuticals; DNAtrix; Global Coalition for Adaptive Research; GW Pharmaceuticals; Inovio Pharmaceuticals; Karyopharm Therapeutics; Katmai Pharmaceuticals; KIYATEC; Merck; Novartis; Pascal Biosciences; Pfizer; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; SERVIER; SonaCare Medical; Tocagen; VBI Vaccines; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Break Through Cancer; Global Coalition for Adaptive Research